Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 12Active not recruiting 5Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 10Gynecologic 5Genitourinary 4Endocrine 4NET 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 4Recurrence 1Endometrial Hyperplasia 1Breast Neoplasms 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Everolimus × Gynecologic × Clear all
NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Gynecologic

Endometrial Neoplasms

NCT01068249 2026-04-30

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled 11 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT02397083 2026-02-13

LEVER

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
102 enrolled
Gynecologic

Endometrial Hyperplasia

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
62 enrolled
Gynecologic

Endometrial Neoplasms

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡